Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07536100

Effectiveness and Tolerability of VENEZE Peptide Factor Hair Serum for Pattern Hair Loss: A Randomized Double-blind Study

Led by Institute of Dermatology, Thailand · Updated on 2026-05-13

80

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

Sponsors

I

Institute of Dermatology, Thailand

Lead Sponsor

M

MEDEZE Cosmeceutical Company Limited

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in adults with androgenetic alopecia (pattern hair loss). This condition affects both men and women and can impact quality of life. The study aims to measure improvement in hair growth, including changes in hair density and thickness, while also assessing safety and patient-reported outcomes. Participants will be randomly assigned in a double-blind manner to apply either the VENEZE peptide factor hair serum or a 2% minoxidil solution topically to the scalp twice daily for 24 weeks. Both treatments are administered according to the study protocol. The study includes two groups: one using the peptide serum and the other using minoxidil as an active comparator. During the study, participants will attend scheduled visits where researchers will measure hair density, hair thickness, and terminal hair count at 12 and 24 weeks. Additional assessments include the Investigator Global Aesthetic Improvement Scale, androgenetic alopecia severity, patient global assessments, and monitoring for any adverse events. Participants are expected to maintain consistent hair color and hairstyle and attend all visits throughout the 24-week treatment period.

CONDITIONS

Brief Title

VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female participants aged 18 years or older
  • Diagnosed with androgenetic alopecia: Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females
  • Able to read and write to complete study questionnaires
  • Willing to comply with study procedures, including maintaining consistent hair color and hairstyle
  • Hair length of 2 cm or more in the non-balding vertex area at each visit
  • Able to attend all scheduled visits during the 24-week study period
Not Eligible

You will not qualify if you...

  • Unstable or uncontrolled systemic diseases affecting hair growth within 6 months prior to screening
  • History of malignancy within past 5 years, except treated basal or squamous cell carcinoma
  • Psychiatric disorders or conditions affecting safety or compliance
  • Pregnant or breastfeeding women
  • Diffuse hair thinning involving the occipital area
  • Scalp diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis)
  • History of hair transplantation or hair extensions within 6 months prior to screening
  • Use of cosmetic hair loss concealment products within 2 weeks prior to screening
  • Use of light/laser scalp therapy within 3 months prior to screening
  • Use of hair growth supplements (e.g., zinc, biotin) within 3 months prior to screening
  • Use of hair products with active ingredients (e.g., caffeine, peptides) within 3 months prior to screening
  • Hair procedures like mesotherapy or stem cell injection within 3 months prior to screening
  • Known hypersensitivity to study products or ingredients
  • Use of dutasteride within 12 months prior to screening
  • Use of systemic cytotoxic agents
  • Use of systemic glucocorticoids within 3 months prior to screening (except non-scalp topical or inhaled corticosteroids)
  • Use within 6 months prior to screening of minoxidil, finasteride, anti-androgenic drugs, prostaglandin analogs, estrogen or progesterone topical preparations, tamoxifen, drugs causing hypertrichosis or hair loss
  • Participation in another clinical trial within 1 month prior to screening or during this study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 24 weeks

Participants apply either the VENEZE peptide factor hair serum or topical 2% minoxidil solution to the scalp twice daily as per the study protocol to treat androgenetic alopecia.

Regular visits during the 24-week treatment period as per study protocol

Trial Site Locations

Total: 2 locations

1

Institute of dermatology

Bangkok, Bangkok, Thailand, 10400

Actively Recruiting

2

Institute of Dermatology

Bangkok, Thailand

Actively Recruiting

Loading map...

Research Team

C

Chinmanat Lekhavat, MD, PhD

S

Suchanaree Laitrakul, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled...

Androgenetic Alopecia (AGA)

Actively Recruiting

1 location

A Pilot Study to Evaluate the Therapeutic Effect of Dihydroa...

Androgenetic Alopecia (AGA)

Actively Recruiting

1 location

PRP Combined With Botulinum Toxin Type A Injection for the T...

Androgenetic Alopecia (AGA)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Ginsenoside Rg4 Enhances the Inductive Effects of Human Dermal Papilla Spheres on Hair Growth Via the AKT/GSK-3β/β-Catenin Signaling Pathway.

Yun Hee Lee, Hui-Ji Choi, Ji Yea Kim...

https://pubmed.ncbi.nlm.nih.gov/34099599

Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium.

Jan Wadstein, Erling Thom, Aida Gadzhigoroeva

https://pubmed.ncbi.nlm.nih.gov/32425997

A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.

Elise A Olsen, David Whiting, Wilma Bergfeld...

https://pubmed.ncbi.nlm.nih.gov/17761356